TearCare in Young Adults
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-29
SponsorUniversity of Alabama at Birmingham
About this trial
This study is a non-randomized, open-label, interventional trial of TearCare® eyelid warming and manual meibomian gland expression in young adults with clinically significant meibomian gland dysfunction (MGD). Intervention is with TearCare® performed at Visit 1. A single follow-up examination occurs at Day 28.
Eligibility criteria
Qualifiers
Age ≥18 years but <30 years of age
Non-invasive Keratograph break-up time (NIKBUT) <10 seconds in at least one eye
Meibomian gland secretion score (MGSS) ≤23 for 15 glands in at least one eyelid
OSDI ≥23
Disqualifiers
Contact lens wear within two weeks of study enrollment or planned during study period
Habitual visual acuity worse than 0.30 logMAR (Snellen equivalent of 20/40) in either eye
Previous or current diagnosis of any autoimmune condition
Topical ophthalmic cyclosporine (including but not limited to Restasis®, Cequa®, Vevye®, generic, or compounded versions)
Trial design
Treatments tested in this trial
- TearCare®
Treatment groups
45 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Alabama at Birmingham
Lead sponsor
Sight Sciences, Inc.
Collaborator
Source ClinicalTrials.gov